Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Angela Gutowski

Nurse Practitioner Hamilton, OH Nurse Practitioner

NPI 1225517444 CMS profile 11204380

1502 University Blvd, Hamilton, OH 45011

Open in the dashboard

General payments

$10,256

631 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Angela Gutowski of Hamilton, OH is reported in the CMS Open Payments database as having received $10,256 across 631 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,718 221
2024 General $2,015 108
2023 General $1,446 76
2022 General $1,452 113
2021 General $1,625 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Gutowski
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Angela Gutowski were reported at $3,718. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Angela Gutowski Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,625 $135 $40–$426 $132
2022 $1,452 $152 $48–$470 $149
2023 $1,446 $166 $54–$529 $160
2024 $2,015 $173 $55–$556 $164
2025 $3,718 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teva Pharmaceuticals USA, Inc. $1,954 86 payments
  2. Alkermes, Inc. $1,436 92 payments
  3. Otsuka America Pharmaceutical, Inc. $1,101 64 payments
  4. Janssen Pharmaceuticals, Inc $942 38 payments
  5. Lundbeck LLC $829 66 payments
  6. AbbVie, Inc. $799 88 payments
  7. Neurocrine Biosciences, Inc. $664 37 payments
  8. ITI, Inc. $588 34 payments
  9. Vanda Pharmaceuticals Inc. $528 21 payments
  10. Sunovion Pharmaceuticals Inc. $435 50 payments
  11. Other $981 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,218 626 payments
  2. Education $38 5 payments
Products named General payments · program years 2021–2025
  1. LYBALVI Cns $1,048 72 payments
  2. ARISTADA Cns $1,031 84 payments
  3. ARISTADA Cns $1,031 84 payments
  4. Austedo XR $911 32 payments
  5. ARISTADA Cns $782 56 payments
  6. ARISTADA Cns $782 56 payments
  7. REXULTI $719 35 payments
  8. ABILIFY MAINTENA $718 57 payments
  9. LYBALVI Cns $654 36 payments
  10. VRAYLAR $645 72 payments
  11. Other $8,080 451 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

3,190

Median for Nurse Practitioner: 389

Drug cost

$1,055,782

Median for Nurse Practitioner: $21,885

Branded share of claims

25.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 68 $219,948
Ingrezza Valbenazine Tosylate Brand 20 $175,828
Abilify Maintena Aripiprazole Brand 49 $145,791
Austedo Xr Deutetrabenazine Brand 11 $130,602
Aristada Aripiprazole Lauroxil Brand 24 $92,414
Rexulti Brexpiprazole Brand 45 $87,904
Vraylar Cariprazine Hcl Brand 45 $73,330
Trintellix Vortioxetine Hydrobromide Brand 52 $40,122
Lurasidone Hcl Generic 54 $15,535
Qelbree Viloxazine Hcl Brand 11 $7,996

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $437
$437 11 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $266
  • Lundbeck LLC $135
$401 45 —
INGREZZA
  • Neurocrine Biosciences, Inc. $149
$149 20 —
VRAYLAR
  • AbbVie, Inc. $148
$148 45 —
ABILIFY MAINTENA
  • Lundbeck LLC $92
  • Otsuka America Pharmaceutical, Inc. $52
$145 49 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

631 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record